Zimmer Biomet Holdings, Inc.
NYSE:ZBH · New York Stock Exchange
+$0.87 today
Vol 1.59M · Avg 2.28M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NYSE:ZBH · Revenue to Net Income
Key Ratios
Analysis
$8.4B of revenue converted into $761.3M of net income for the selected period. Gross margin is 70.2% and net margin is 9.1%, showing how much revenue survives after costs and taxes. EPS is $3.85, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.2B +7.2% | $7.7B +3.8% | $7.4B +6.5% | $6.9B +1.6% | $6.8B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $3.2B +44.2% | $2.2B +5.2% | $2.1B +3.2% | $2.0B +3.0% | $2.0B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $5.1B -7.6% | $5.5B +3.3% | $5.3B +7.9% | $4.9B +1.1% | $4.9B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 61.6% -9.8pp | 71.5% -0.4pp | 71.8% +0.9pp | 70.9% -0.4pp | 71.3% | 9.8% | 28.9% | 38.3% |
| Research & Development | $458.5M +4.8% | $437.4M -4.6% | $458.7M +13.0% | $406.0M -6.8% | $435.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $3.3B +11.0% | $2.9B +3.2% | $2.8B +2.8% | $2.8B -2.9% | $2.8B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $3.7B -11.7% | $4.2B +4.2% | $4.0B -4.5% | $4.2B +5.4% | $4.0B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.1B +9.8% | $996.3M +4.7% | $951.7M +2.7% | $926.4M -1.2% | $937.7M | $374.2M | $1.2B | $631.8M |
| EBITDA | $2.2B -1.5% | $2.3B +1.4% | $2.2B +48.5% | $1.5B -9.1% | $1.6B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 26.9% -2.4pp | 29.3% -0.7pp | 30.0% +8.5pp | 21.5% -2.6pp | 24.1% | 5.6% | 46.3% | 42.0% |
| Operating Income | $1.4B +6.0% | $1.3B +0.6% | $1.3B +83.5% | $696.3M -19.1% | $860.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 16.5% -0.2pp | 16.7% -0.5pp | 17.3% +7.2pp | 10.0% -2.6pp | 12.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $292.8M +34.3% | $218.0M +8.3% | $201.2M +22.1% | $164.8M -20.9% | $208.4M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$531.4M -113.3% | -$249.1M -18.4% | -$210.4M +28.1% | -$292.8M +19.0% | -$361.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $830.8M -19.9% | $1.0B -2.9% | $1.1B +164.5% | $403.5M -19.1% | $499.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 10.1% -3.4pp | 13.5% -0.9pp | 14.4% +8.6pp | 5.8% -1.5pp | 7.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $125.7M -4.3% | $131.4M +211.4% | $42.2M -62.4% | $112.3M +109.9% | $53.5M | $1.3B | -$1.6B | $745.2M |
| Net Income | $705.2M -22.0% | $903.8M -11.7% | $1.0B +342.5% | $231.4M -42.4% | $401.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | 8.6% -3.2pp | 11.8% -2.1pp | 13.8% +10.5pp | 3.3% -2.5pp | 5.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $4 -20.0% | $4 -9.4% | $5 +346.4% | $1 -43.0% | $2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $4 -19.9% | $4 -9.2% | $5 +343.6% | $1 -42.4% | $2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $198.0M -2.5% | $203.1M -2.7% | $208.7M -0.4% | $209.6M +0.5% | $208.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $198.7M -2.6% | $203.9M -2.8% | $209.7M -0.3% | $210.3M -0.0% | $210.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
DexCom, Inc.
NASDAQ:DXCM
$27.95B
Illumina, Inc.
NASDAQ:ILMN
$24.50B
West Pharmaceutical Services, Inc.
NYSE:WST
$23.17B
Waters Corporation
NYSE:WAT
$23.17B
United Therapeutics Corporation
NASDAQ:UTHR
$22.76B
Quest Diagnostics Incorporated
NYSE:DGX
$21.58B
Labcorp Holdings Inc.
NYSE:LH
$20.98B
STERIS plc
NYSE:STE
$19.74B
Incyte Corporation
NASDAQ:INCY
$19.62B
Smith & Nephew plc
NYSE:SNN
$12.74B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ZBH generate?
Zimmer Biomet Holdings, Inc. (ZBH) reported $8.23B of revenue in fiscal 2025.
Is ZBH profitable?
Zimmer Biomet Holdings, Inc. (ZBH) reported $705.20M of net income, with a net margin of 8.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.